Literature DB >> 15303464

Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis.

Ajay Duseja1, Mohit Nanda, Ashim Das, Reena Das, Anil Bhansali, Yogesh Chawla.   

Abstract

Non-alcoholic steatohepatitis (NASH) is emerging as an important cause of cryptogenic cirrhosis. Obesity, diabetes mellitus and hyperlipidaemia are important risk factors for NASH. The presence of these risk factors in patients with cryptogenic cirrhosis may suggest NASH as an aetiology of cirrhosis in them. Twenty-five patients of cryptogenic cirrhosis were compared with 18 patients of hepatitis B virus and hepatitis C virus related cirrhosis and primary biliary cirrhosis for the presence of obesity, diabetes mellitus and hyperlipidaemia. Patients with cryptogenic cirrhosis were found to have a significantly higher body - mass index increased prevalence of diabetes mellitus and lower high-density lipoprotein compared to the controls. Increased body weight and diabetes mellitus may play a role in the causation of cirrhosis in patients with cryptogenic cirrhosis.

Entities:  

Mesh:

Year:  2004        PMID: 15303464

Source DB:  PubMed          Journal:  Trop Gastroenterol        ISSN: 0250-636X


  11 in total

Review 1.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

2.  Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation.

Authors:  Ajay Duseja; Ashim Das; Radha Krishan Dhiman; Yogesh Kumar Chawla; Reena Das; Sanjay Bhadada; Ravinder Sialy; Kiran Kumar Thumburu; Anil Bhansali; Naveen Kalra
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease in India - a lot done, yet more required!

Authors:  Ajay Duseja
Journal:  Indian J Gastroenterol       Date:  2010-12-30

4.  Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin.

Authors:  Deepa Rana; Ajay Duseja; Radha K Dhiman; Yogesh Chawla; Sunil K Arora
Journal:  Hepatol Int       Date:  2012-05-06       Impact factor: 6.047

5.  Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients.

Authors:  Matthew Kroh; Rockson Liu; Bipan Chand
Journal:  Surg Endosc       Date:  2007-05-04       Impact factor: 4.584

6.  HCV infection and cryptogenic cirrhosis are risk factors for hepatocellular carcinoma among Latinos in New York City.

Authors:  Rafael Guerrero-Preston; Abby Siegel; John Renz; David Vlahov; Alfred Neugut
Journal:  J Community Health       Date:  2009-12

7.  The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West.

Authors:  Ajay Duseja; Ashim Das; Reena Das; R K Dhiman; Y Chawla; A Bhansali; Naveen Kalra
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

8.  Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease.

Authors:  Ram V Nampoothiri; Ajay Duseja; Manish Rathi; Swastik Agrawal; Naresh Sachdeva; Manu Mehta; Harpal S Dhaliwal; Radha K Dhiman; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2017-12-30

9.  Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions.

Authors:  Yong-Jik Lee; Yoo-Na Jang; Yoon-Mi Han; Hyun-Min Kim; Jong-Min Jeong; Hong Seog Seo
Journal:  PPAR Res       Date:  2017-03-13       Impact factor: 4.964

10.  Diabetes and risk of cancer.

Authors:  Samy L Habib; Maciej Rojna
Journal:  ISRN Oncol       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.